EcoDrugPlus

Histone Deacetylase 11

Ensembl ID : ENSAOCG00000023583
Gene Symbol: HDAC11
3 Cross references
200 Possible Orthologues:

Histone Deacetylase 2

Ensembl ID : ENSAOCG00000008362
Gene Symbol: HDAC2
4 Cross references
205 Possible Orthologues:

Histone Deacetylase 3

Ensembl ID : ENSAOCG00000007417
Gene Symbol: HDAC3
4 Cross references
155 Possible Orthologues:

Histone Deacetylase 4

Ensembl ID : ENSAOCG00000023072
Gene Symbol: HDAC4
4 Cross references
196 Possible Orthologues:

Histone Deacetylase 4-Like

Ensembl ID : ENSAOCG00000011017
Gene Symbol: LOC111583580
3 Cross references
202 Possible Orthologues:

Histone Deacetylase 5

Ensembl ID : ENSAOCG00000015179
Gene Symbol: HDAC5
3 Cross references
195 Possible Orthologues:

Histone Deacetylase 6

Ensembl ID : ENSAOCG00000011803
Gene Symbol: HDAC6
3 Cross references
179 Possible Orthologues:

Histone Deacetylase 7

Ensembl ID : ENSAOCG00000023833
Gene Symbol: HDAC7
1 Cross references
196 Possible Orthologues:

Histone Deacetylase 7

Ensembl ID : ENSAOCG00000021960
Gene Symbol: HDAC7
3 Cross references
196 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSAOCG00000001389
Gene Symbol: HDAC8
3 Cross references
206 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSAOCG00000019593
Gene Symbol: HCN4
3 Cross references
219 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSAOCG00000005654
Gene Symbol: HCN4
3 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).